Chemo­Cen­tryx grabs $50M up­front, adds de­vel­op­ment part­ner­ship with Vi­for

Sev­en months af­ter Vi­for swooped in to bag the Eu­ro­pean rights to Chemo­Cen­tryx’s C5a-tar­get­ing CCX168 with an $85 mil­lion down pay­ment, the Swiss com­pa­ny has come back with $50 mil­lion more in cash to grab an­oth­er one of the biotech’s ex­per­i­men­tal drugs.

To start, these part­ners plan to fo­cus their at­ten­tion on rare kid­ney dis­eases for CCX140, with Vi­for hold­ing an op­tion on chron­ic kid­ney dis­ease. Chemo­Cen­tryx $CCXI is keep­ing US and Chi­na rights ini­tial­ly while Vi­for holds the li­cense on the rest of the world. And if Vi­for takes its broad­er op­tion on CKD, Chemo­Cen­tryx can keep co-pro­mo­tion rights in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER